Recursion Pharmaceuticals Newsroom

10 Health Care Stocks Whale Activity In Today's Session

Benzinga12:35 ET

Why Recursion Pharmaceuticals (RXRX) Is the Worst ARK Stock to Buy According to Short Sellers

Yahoo Finance11:48 ET

Needham Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $11

Moomoo NewsDec 11 09:33 ET · Ratings

Express News | Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $11 Price Target

BenzingaDec 11 08:26 ET

Recursion Pharmaceuticals Analyst Ratings

BenzingaDec 11 08:25 ET · Ratings

TD Cowen Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating

Moomoo NewsDec 11 07:31 ET · Ratings

TD Cowen Keeps Their Hold Rating on Recursion Pharmaceuticals (RXRX)

TipRanksDec 11 07:25 ET · Ratings

BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Maintains Target Price $12

Moomoo NewsDec 11 05:34 ET · Ratings

Cautious Optimism for Recursion Pharmaceuticals Amid Promising Safety Profile and Upcoming Milestones

TipRanksDec 11 05:15 ET

10 Health Care Stocks With Whale Alerts In Today's Session

BenzingaDec 10 12:35 ET

What's Going On With Recursion Pharmaceuticals Stock?

BenzingaDec 10 09:55 ET

Recursion Pharmaceuticals Says Potential Advanced Solid Tumor Treatment Well Tolerated

MT NewswiresDec 10 05:03 ET

Recursion Reports Promising Phase 1/2 Data for REC-617, a CDK7 Inhibitor, in Advanced Solid Tumors

Quiver QuantitativeDec 9 18:10 ET

Express News | Recursion Pharmaceuticals Inc: Plans to Continue Monotherapy Dose Escalation and Initiate Combination Studies in 1H 2025

ReutersDec 9 18:05 ET

Express News | Recursion Pharmaceuticals Inc: REC-617 Well-Tolerated With No Discontinuations Due to Adverse Events

ReutersDec 9 18:04 ET

Express News | Recursion Pharmaceuticals: 4 Patients Demonstrated a Best Response of Stable Disease for up to 6 Months of Treatment

ReutersDec 9 18:03 ET

Express News | Recursion Pharmaceuticals Inc: Confirmed Partial Response in Platinum-Resistant Ovarian Cancer Patient

ReutersDec 9 18:02 ET

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

GlobeNewswireDec 9 18:00 ET

Express News | Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class Cdk7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

ReutersDec 9 18:00 ET

Trending Industry Today: Nano X Imaging Leads Gains Pre-Market In NVIDIA Portfolio Stocks

Moomoo NewsDec 9 04:10 ET